The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wipke, B. T.
Right arrow Articles by Allen, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wipke, B. T.
Right arrow Articles by Allen, P. M.
The Journal of Immunology, 2001, 167: 1601-1608.
Copyright © 2001 by The American Association of Immunologists

Essential Role of Neutrophils in the Initiation and Progression of a Murine Model of Rheumatoid Arthritis1

Brian T. Wipke and Paul M. Allen2

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Neutrophils are prominent participants in the joint inflammation of human rheumatoid arthritis (RA) patients, but the extent of their role in the inductive phase of joint inflammation is unknown. In the K/BxN mouse RA model, transfer of autoreactive Ig from the K/BxN mouse into mice induces a rapid and profound joint-specific inflammatory response reminiscent of human RA. We observed that after K/BxN serum transfer, the earliest clinical signs of inflammation in the ankle joint correlated with the presence of neutrophils in the synovial regions of recipient mouse ankle joints. In this study, we investigated the role of neutrophils in the early inflammatory response to transferred arthritogenic serum from the K/BxN transgenic mouse. Mice were treated with a neutrophil-depleting mAb before and following transfer of arthritogenic serum and scored for clinical indications of inflammation and severity of swelling in ankle joints and front paws. In the absence of neutrophils, mice were completely resistant to the inflammatory effects of K/BxN serum. Importantly, depletion of neutrophils in diseased recipient mice up to 5 days after serum transfer reversed the inflammatory reaction in the joints. Transfer of serum into mice deficient in the generation of nitrogen or oxygen radicals (inducible NO synthase 2 or gp91phox genes, respectively) gave normal inflammatory responses, indicating that neither pathway is essential for disease induction. These studies have identified a critical role for neutrophils in initiating and maintaining inflammatory processes in the joint.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Rheumatoid arthritis (RA)3 in humans is a debilitating and chronic autoimmune disease characterized by chronic inflammation of the distal joints. Affected joints display hyperplasia of the synovia with increased synovial fluid volume, large cellular infiltrates of several cell types (neutrophils, macrophages, fibroblasts, T cells, and dendritic cells) in the synovial and periarticular regions, complement deposition, high levels of proinflammatory cytokine expression, and eventual erosion and remodeling of the cartilage and bone of the joint (reviewed in Refs. 1, 2). However, it has been difficult to study the initial stages of disease because afflicted individuals are normally diagnosed after the onset of severe and chronic joint inflammation. Small animal models of arthritis in which disease induction is synchronized and predictable allow investigators to determine the contributions of specific cell types and effector molecules to the multiple steps of disease induction and pathogenesis.

The most extensively used small animal model of RA is type II collagen-induced arthritis (CIA) (3, 4, 5, 6, 7), in which immunization of mice with heterologous type II collagen in adjuvant induces a cross-reactive immune response to murine type II collagen. This autoimmune reaction is mediated by immune complex formation and shares many characteristics with human RA (reviewed in Ref. 8). Synovial inflammation (synovitis) can be induced with single mAbs specific for type II collagen (9), and mixtures of type II collagen-specific mAbs against specific regions of collagen cannot only induce synovitis, but also cause clinical arthritis (10), indicating that anti-collagen Ab deposition in the joints triggers the complete range of arthritic symptoms. The CIA model has also been useful for studies of cytokine expression in the synovium and synovial fluid compartments (8), determination of the relative roles of complement (6) and Ig Fc receptors in disease initiation and pathogenesis (reviewed in Ref. 11), and development of effective anti-inflammatory therapeutics such as neutralizing Abs to IL-1 (12, 13) and TNF-{alpha} (14, 15, 16).

Recently, a spontaneous murine disease with most of the characteristics of human RA was fortuitously discovered by breeding the KRN transgenic TCR, specific for bovine RNase (42–56)/I-Ak, mouse to the nonobese diabetic (NOD) background (17). The F1 generation between KRN and NOD (abbreviated K/BxN) spontaneously develops a progressive joint-specific autoimmune disease between 3 and 5 wk of age, characterized by rapid symmetrical onset of peripheral joint inflammation that is restricted primarily to the joints of the front and rear limbs. Pathology of disease in K/BxN mice is similar to human RA, with pannus formation, synovial hyperplasia, increased synovial fluid volume, cellular infiltrates, and chaotic remodeling of cartilage and bone in the distal joints in later stages. The K/BxN mouse model also exhibits elevated expression of proinflammatory cytokines, hypergammaglobulinemia, and autoreactive Ab production (18), all of which can be found in human RA patients. One difference between the two diseases is the absence of detectable rheumatoid factor in K/BxN mice (17), although ~20–30% of human RA patients are also negative for serum rheumatoid factor (19). Immune complexes of rheumatoid factor-IgG and potentially other Ab-Ag immune complexes can be found in the joints of human RA patients (20), but their role in joint pathology and disease progression has yet to be ascertained.

In the K/BxN model, KRN TCR transgenic cells recognize a mouse (self)-derived peptide bound to I-Ag7, presented by B cells and other MHC class II-positive APCs (18). The autoantigen for both K/BxN arthritogenic Ig and KRN T cells was recently identified (21) as glucose-6-phosphate isomerase (GPI), an ubiquitous cytoplasmic enzyme that catalyzes the interconversion of fructose-6-phosphate and glucose-6-phosphate during glycolysis. Our laboratory has recently established the molecular basis for the dual ability of the KRN TCR to recognize RNase (42–56)/I-Ak and GPI (282–294)/I-Ag7 (22, 23). A working model of K/BxN disease initiation postulates that GPI-specific B cells endocytose GPI via surface Ig receptors and present the I-Ag7-restricted epitope to incompletely tolerized CD4+ KRN T cells, which in turn provide specific help in maturation and Ig isotype switching, leading to autoantibody production (17, 18, 21) and subsequent induction of joint inflammation.

Transfer of serum or purified Ig from arthritic K/BxN mice induces a synchronized joint-specific inflammatory reaction that mimics the K/BxN disease (18), indicating that arthritogenic Ig can induce synovitis and rheumatoid-like arthritic disease. The disease induced by a single administration of serum eventually resolves, unless arthritogenic Ig is repeatedly transferred into recipients (18). The development of an easily inducible model of RA with a rapid, synchronized onset facilitates the study of the pathogenic mechanisms involved in the initiation of joint autoimmunity.

In this study, we found that neutrophils play an indispensable role in disease initiation in the K/BxN serum transfer model of RA. We used a mAb to deplete neutrophils in recipient mice and found that this treatment completely blocked the acute joint-specific inflammatory response normally induced by K/BxN serum transfer, and caused rapid and profound reversal of joint inflammation in diseased mice. Furthermore, we determined that neither the inducible NO synthase (iNOS)2 nor gp91phox gene products are required for the serum-induced joint inflammation.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Mice

NOD mice (6–8 wk old) were obtained from Taconic Farms (Germantown, NY). KRN TCR transgenic mice on a B6 background (K/B, the generous gift of D. Mathis and C. Benoist, Harvard Medical School, Boston, MA) were bred to NOD mice to generate K/BxN mice. Mice deficient for iNOS2 (24) or gp91phox (25) gene expression, C57BL/6J, B6.AKR (H-2k), CB.17-SCID, and B6.AKR-RAG1-/- mice were obtained from The Jackson Laboratory (Bar Harbor, ME), and bred and housed under specific pathogen-free conditions in the animal colony at Washington University (St. Louis, MO). All mice were sex matched and age matched for experiments, and were between 6 and 10 wk of age.

Arthritic serum

Serum was separated from blood obtained from arthritic K/BxN mice (6–12 wk old) and frozen at -70°C. To prepare larger pools for in vivo experiments, frozen serum samples were thawed, centrifuged at 12,000 rpm for 10 min, pooled and sterile filtered, and frozen in aliquots at -70°C. Before injection, serum aliquots were thawed, centrifuged, and diluted with PBS. Each batch of pooled serum was titrated in B6.AKR mice (groups of 3–5 mice per dose) for its ability to transfer joint-specific disease and to determine an effective dose of serum for subsequent serum transfer experiments. A dose of 250 µl per mouse was selected, as it consistently gave disease induction in 100% of the mice.

Antibodies

The rat IgG2b mAb RB6-8C5 (26) was purified using protein G-Sepharose 4 Fast Flow affinity matrix (Pharmacia, Piscataway, NJ) from ascites produced in SCID mice. GK1.5 mAb (27) against mouse CD4 (rat IgG2b) was purified from ascites by saturated ammonium sulfate precipitation (45% final) and dialysis against PBS, pH 7.4, before being stored at -70°C.

Ab depletion in vivo

For in vivo neutrophil depletion, 250 µg RB6-8C5 mAb was diluted to 0.5 ml with PBS and injected i.p. at 3-day intervals beginning 1 day before serum transfer, except for the experiment described in Fig. 4Go. This dose of Ab is equal to or greater than has been shown previously to be efficacious in completely eliminating neutrophils in vivo (28, 29, 30). We determined in early experiments that a single injection of RB6-8C5 is not sufficient to completely block joint inflammation for more than ~5–6 days, as demonstrated by the appearance of clinical signs of inflammation and measurable thickening of the ankle joints. We attribute this to clearance of the RB6-8C5 Ab from the bloodstream and tissues and the maturation and release of new neutrophils from the bone marrow. Previous studies of peripheral blood cell types in RB6-8C5-treated mice have established that macrophage, NK, and T and B lymphocyte populations are not significantly affected by such methods (31, 32, 33, 34, 35, 36, 37). Several studies have demonstrated that RB6-8C5 Ab fails to bind to mature macrophages, monocytes, or splenic B and T lymphocytes by either flow cytometry analysis (32, 36) or immunofluorescent microscopy (33). CD8+ T cells have been previously reported to be moderately affected by RB6-8C5 treatment (36, 38, 39), but the effect on CD8+ cells occurs several days after neutrophils are depleted (38), and would be of no consequence in this model, as T cell-deficient RAG1 mice are equally susceptible to disease (see Fig. 2Go, D and E). For the control anti-CD4 Ab, 50 µl ammonium sulfate-precipitated GK1.5 mAb was diluted to 0.5 ml with PBS and injected i.p. Depletion was monitored by flow cytometry using biotinylated RB6-8C5 and GK1.5 (PharMingen, San Diego, CA) and streptavidin-R-PE (Caltag, Burlingame, CA) using standard procedures. A minimum of 20,000 total events was collected using a FACSCalibur and analyzed using CellQuest software (BD Biosciences, Mountain View, CA). Gates and histograms were set using untreated B6.AKR peripheral blood stained with RB6-8C5 or GK1.5.



View larger version (21K):
[in this window]
[in a new window]
  		FIGURE 4. Mice deficient in iNOS2 and gp91phox gene expression develop joint inflammation with kinetics similar to control B6 mice. Mice were injected with K/BxN serum (200 µl i.p.) and monitored daily for changes in ankle thickness (A) and clinical index score (B). Representative results from one of three identical experiments are shown. There were no instances in which iNOS2 knockout or gp91phox knockout mice were significantly more resistant to serum-induced joint inflammation than B6 control mice, and in two experiments iNOS2 knockout mice appear to have slightly enhanced inflammation relative to B6 mice.

 


View larger version (41K):
[in this window]
[in a new window]
  		FIGURE 2. Depletion of neutrophils by administration of RB6-8C5 Ab renders mice resistant to K/BxN serum-induced joint inflammation. Data from two similar experiments are shown in A–C and D–F, respectively. Groups of five mice were treated with either PBS (0.5 ml), RB6-8C5 (250 µg each) or GK1.5 mAb (50 µl purified ascites each, A–C only) by injection i.p. on days -1, 2, and 5 as indicated by arrows on the x-axis. On day 0, each mouse received 250 µl K/BxN serum i.p. A and D, Depletion of neutrophils, but not CD4+ T cells prevents joint inflammation. Mean ankle thicknesses were determined daily for each group of mice by measuring the width of ankles across the medial-lateral axis of the joint. SDs for mean ankle thickness are indicated by error bars. B and E, Neutrophil-depleted mice show no clinical signs of joint inflammation. Clinical index scores correlate closely with ankle thickness changes in control groups of mice. Clinical index scores were determined daily and are presented as the mean clinical score for each group of mice, with SDs indicated by error bars. C and F, Percentage of PBL staining positively with RB6-8C5 Ab was determined on days 2, 5, and 7 for each group of mice by Ab staining and flow cytometry, as described in Materials and Methods. Data are presented as the mean percentage of total PBL staining positively with RB6-8C5 mAb. SD values are indicated by the presence of error bars. The mean percentage for the RB6-8C5-treated group never exceeded 2% of total PBL in either experiment. RB6-8C5 staining for GK1.5-treated mice was nearly identical with that of PBS-treated mice (data not shown). These experiments with GK1.5 mAb depletion as a control (A–C) and RAG1-deficient recipients (D–F) were performed twice with identical results. In addition, neutrophil depletion by RB6-8C5 Ab treatment (days -1, 2, and 5) has been used in a total of six experiments and >30 wild-type mice with similar protection from disease.

 
K/BxN serum transfer model

Serum as prepared above was injected i.p., and clinical scores were determined daily based upon evidence of redness and swelling, using a scale ranging from 0 to 4, as described previously (17). Physical measurement of ankle thickness was performed using a Fowler Metric Pocket Thickness Gauge (Ralmikes Tool-A-Rama, Middlesex, NJ). Ankle measurements were made above the footpad, axially across the ankle joint, and rounded off to the nearest 0.05 mm. Data are presented as the mean of individual ankle thicknesses within a group of mice (3–6 mice per group). Mean percent inhibition of ankle swelling due to RB6-8C5 depletion was calculated using the following formula: 1 - (experimental mean ankle thickness - experimental baseline mean ankle thickness)/(PBS mean ankle thickness - PBS baseline mean ankle thickness). Student t tests for paired data were performed using Kaleidagraph software (Synergy Software, Reading, PA) on calculated values from data of three identical experiments, with a total of 12 mice per experimental condition.

Histology

Tissue samples were prepared by fixing tissues 24–48 h in 10% phosphate-buffered Formalin (J. T. Baker, Phillipsburg, NJ). Fixed joints were decalcified by treatment with Decal Overnight Bone Decalcifier solution (Decal Chemical, Congers, NY) for 2 days with gentle rocking and daily replacement of the Decal solution. Samples were then washed with PBS, dehydrated with a series of ethanol washes (50% ethanol, followed by 70% ethanol), and embedded in paraffin. Sections of tissue 4 µm thick were stained with H&E. Representative sections from individual mice within groups of three to six mice were selected to illustrate the general state of each group’s ankle joints.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Polymorphonuclear neutrophils were found in periarticular and synovial regions of ankle joints within 48 h of serum transfer

To determine the timing of inflammatory cell recruitment to affected joints following K/BxN serum transfer, we performed histological studies on ankle joints over time. Injection of serum reproducibly resulted in rapid bilateral ankle swelling (Fig. 1GoA) and increased clinical index scores (Fig. 1GoB) in B6.AKR mice within 24–48 h post transfer. Ankles continued to increase in size up to 7 days post transfer.



View larger version (94K):
[in this window]
[in a new window]
  		FIGURE 1. Joint inflammation occurs within 48 h of serum transfer, and neutrophils are found in ankle joints at the onset of inflammation. A and B, Kinetics of joint inflammatory disease caused by transfer of K/BxN serum. A representative group of mice (n = 3) received a single injection of 250 µl K/BxN serum i.p., and were monitored for changes in ankle thickness and clinical index score. Detectable swelling and inflammation occur within 48 h. Results shown are from one experiment and are representative of more than five experiments. C–H, Histological time course of cellular infiltration into periarticular and intraarticular spaces following serum transfer. Mice received a single injection of 250 µl K/BxN serum i.p., and ankle joints were harvested at 12- to 24-h increments, treated for histology as detailed in Materials and Methods, and stained with H&E. Shown are ankle cross-sections of a normal B6.AKR mouse (C), and serum recipient mice at 24 h (D), 40 h (E and F), and 48 h (G and H), which are representative of the general inflammatory response in multiple mice for each time point. Photographs of representative ankle joint sections are shown at magnifications of x50 (C–E) and x500 (F–H).

 
Sagittal sections of hind ankles through the center of the joint 12 h after serum transfer showed no change in the size or condition of the ankle and metatarsal joints compared with control mice (data not shown). Twenty-four hours after serum transfer, the ankle joint (Fig. 1Go, A and B) and wrist joint (data not shown) were inflamed, with redness (erythema), tenderness, and measurable ankle swelling. Histological examination at 24 h (Fig. 1GoD, x50 magnification) revealed a slight increase in the size of the articular space contained within the synovium, as evidenced by a larger gap between the talus and the synovial membrane, consistent with observed edema in the region. The synovial fluid space was clear and free of cellular infiltrate, and the synovial membrane appeared normal (data not shown). Thirty-six to forty hours after serum transfer, ankle joints continued to increase in thickness and clinical index severity, with nearly all of the extremities involved (Fig. 1Go, A and B). Histology of the ankle joints at this time showed an increased synovial fluid volume and the presence of neutrophils in the synovial fluid surrounding the talus, calcaneus, and distal tibia/fibula (Fig. 1Go, E, x50 magnification, and F, x500 magnification). Neutrophils also began to accumulate in the loose connective tissue posterior to the ankle joint between the Achilles tendon and the talus, and also in the tissues surrounding the synovium on the lateral and anterior portions of the ankle joint.

At 48 h, all of the mice showed significant outward signs of ankle joint inflammation and swelling, with mean ankle sizes increased ~20% in diameter (Fig. 1GoA). Histological analysis at 48 h showed initial signs of synovial membrane expansion surrounding the articular spaces of the joint, with neutrophils and other infiltrating cells in close proximity to the joint spaces and in the synovial fluid (Fig. 1Go, G and H, x500 magnification). Neutrophil numbers were greatly increased, infiltrating the low density connective tissue found posterior to the ankle joints, and also on the sides of the ankle joint just below the malleoli of the tibia and fibula (data not shown).

Neutrophil depletion in vivo dramatically blocked the ability of K/BxN arthritogenic serum to induce joint-specific inflammatory reactions in serum transfer recipients

To further investigate the role of neutrophils in the serum transfer model, we used a depleting mAb (RB6-8C5) specific for a neutrophil-restricted surface marker (Ly-6G), which has been used in numerous unrelated studies to deplete neutrophils in vivo (31, 32, 33, 34, 35, 36, 37). B6.AKR mice were treated with purified RB6-8C5 rat mAb or vehicle alone (PBS) on days -1, 2, and 5 by i.p. injection (250 µg per injection), and K/BxN serum was injected i.p. on day 0. Clinical score and ankle thickness were monitored for 7 days after serum transfer, and the efficiency of neutrophil depletion in peripheral blood was monitored by flow cytometry. Data from two such RB6-8C5 depletion experiments and their associated FACS monitoring of peripheral blood are shown in Fig. 2Go. In the first experiment (Fig. 2Go, A–C), B6.AKR mice were treated with either three doses of RB6-8C5, PBS, or the isotype-matched CD4-depleting rat Ab GK1.5 beginning 1 day before serum transfer (day -1). Mice treated with RB6-8C5 showed no signs of clinical disease through day 7 post transfer (Fig. 2Go, A and B). We found that there was no observable difference between groups treated with either PBS or GK1.5 in either the severity of ankle swelling (Fig. 2GoA) or clinical index scores (Fig. 2GoB). There also was no difference in the time of onset for inflammation, as both groups of mice showed measurable swelling at 2 days post transfer and peaked on days 6–7. The extremities of the PBS- and GK1.5-treated groups became reddened and inflamed within 48 h, while the ankles and wrists of RB6-8C5-treated mice showed no signs of inflammatory response and were indistinguishable from those of control mice that did not receive serum.

Depletion of RB6-8C5-positive peripheral blood leukocytes was essentially complete 1 day after treatment and remained extremely low (<1% of total PBL) throughout the experiment (Fig. 2GoC). Additionally, analysis of FACS plots of forward light scatter vs side light scatter demonstrated the near-total absence of cells in the neutrophil region of the plot, which in normal mice is >95% positive for RB6-8C5 staining (data not shown). CD4+ T cells were completely absent from the peripheral blood of GK1.5-treated mice by FACS analysis (data not shown), yet the progression and severity of serum-transferred disease were unaffected, showing that the protective effect was specific for the depletion of neutrophils.

In addition to its effect on neutrophils, RB6-8C5 mAb treatment has been reported to lead to a slow reduction in the number of CD8+ T cells over the course of several days (36, 38, 40). To ensure that the protective effect of RB6-8C5 mAb treatment was not due to depletion of CD8+ T cells, serum transfer disease was evaluated in RAG1-deficient mice (RAG1-/-), which lack B and T cells. There was no significant difference between RAG1-deficient B6.AKR and wild-type B6.AKR mice in relation to the onset of inflammation, progression, or severity of disease following serum transfer, demonstrating that T and B lymphocytes were dispensable in the serum transfer model. Furthermore, RB6-8C5 mAb treatment protected RAG1-deficient mice from disease induction (Fig. 2Go, D and E). Collectively, the results demonstrated that K/BxN Ig were unable to induce this joint-specific reaction in recipient mice in the absence of a normal neutrophil compartment. This indicates that RB6-8C5-positive neutrophils play an important role in initiating this Ab-mediated disease.

Protection against K/BxN serum-induced joint swelling by RB6-8C5 neutrophil depletion correlates with normal ankle morphology and absence of cellular infiltrates

The ankles of RB6-8C5-treated mice showed remarkably normal morphology at 5 and 7 days postserum transfer, virtually indistinguishable from that of a normal mouse ankle. Ankles from RB6-8C5-treated mice 5 days after serum transfer showed no signs of inflammatory infiltrate or synovial hyperplasia (Fig. 3Go, C and D). In contrast, ankles of PBS-treated mice demonstrated massive inflammatory infiltrate, increased synovial fluid volume, and synovial hyperplasia with large numbers of neutrophils present in the synovial fluid (Fig. 3Go, A and B). The lack of detectable infiltration and synovial hypertrophy in these histological studies of neutrophil-depleted mice correlates with the absence of measurable swelling (Fig. 2GoA) or visible inflammation (Fig. 2GoB), indicating that the presence and infiltration of neutrophils are obligatory for the characteristic changes induced by transfer of K/BxN serum. Therefore, neutrophils must possess properties or functions that are important or even indispensable for the inflammatory response triggered by K/BxN Ig transfer.



View larger version (120K):
[in this window]
[in a new window]
  		FIGURE 3. Histological examination of ankle cross-sections from RB6-8C5-treated and PBS-treated mice 5 days after serum transfer reveals clear differences in joint pathology. Ankles from mice in Fig. 2GoA–C were harvested, fixed, and decalcified. Paraffin-embedded samples were cross-sectioned through the center of the ankle joint and stained with H&E. Representative portions of tissue cross-sections are presented in A–D. A, Low power magnified view (x50) of ankle joints from PBS-treated mouse on day 5. The area shown encompasses a portion of the calcaneus, talus, and fibula/tibia bones. The synovial fluid and pannus show massive cellular infiltrate. Infiltrating cells are visible in synovial fluid spaces of joints and as masses of cells in the connective tissue area between ankle joint and the Achilles tendon. B, High power magnified view (x500) of boxed area indicated in A. Infiltrating neutrophils are visible in synovial fluid spaces and synovium. C, Low power (x50) magnified view of ankle cross-section from day 5 RB6-8C5-treated mouse in same region as in A. Note normal appearance of synovium and complete absence of infiltrating cells in surrounding tissues. D, High power magnified view (x500) of boxed region in C from RB6-8C5-treated mouse on day 5 post transfer. Synovium appears normal in size and morphology, and joint is free of cellular infiltrate, with normal synovial fluid volume. These results are representative of five separate experiments.

 
Testing of mice deficient for generation of reactive nitrogen species and reactive oxygen species in the K/BxN serum transfer model

To begin to determine the mechanism(s) by which neutrophils may act to induce joint disease, we assessed the responses of mice deficient for iNOS2 (iNOS2 knockout mice), which are unable to generate NO (24), and gp91phox-deficient mice that are unable to generate hydrogen peroxide by the NADPH-dependent pathway (25). Results from one of three experiments are shown in Fig. 4Go, in which we found that relative to congenic B6 mice, gp91phox-deficient mice and iNOS2 knockout mice developed arthritis with similar kinetics (Fig. 4Go, A and B). In two of three experiments, we observed slightly enhanced inflammation in iNOS2 knockout mice relative to B6 and gp91phox-deficient mice. Neither strain proved to be more resistant than B6 mice to the inflammation induced by K/BxN serum transfer. Histological analysis of ankle joints from these strains of mice failed to reveal any gross differences in joint morphology (data not shown), suggesting that neither reactive intermediate pathway is critical for the neutrophil-dependent inflammatory response to K/BxN serum.

Reversal of K/BxN serum transfer inflammation with neutrophil depletion via RB6-8C5 treatment

The depletion of neutrophils before serum transfer prevents disease. It was next important to determine whether neutrophil depletion could affect disease progression after the transfer of serum. Groups of B6.AKR mice were treated with a single i.p. injection of 250 µg RB6-8C5 on days -1, 0, 1, 2, or 3 days after K/BxN serum was transferred. This protocol differed from our previous ones, in that we were only administering a single dose of RB6-8C5.

A single injection of RB6-8C5 was equally effective in completely preventing joint inflammation for ~6 days, regardless of whether it was administered 1 day before serum transfer (day -1) or at the same time as serum (day 0, Fig. 5Go, B and C). At 1 day after serum transfer, the remaining untreated groups of mice demonstrated visible signs of inflammation similar to mice in Figs. 1Go and 2 (data not shown) and only slightly elevated ankle measurements (Fig. 5Go, D–G). Treatment with RB6-8C5 beginning 1 day after serum transfer (day +1) immediately and effectively blocked inflammation and clinical manifestations of the disease within 24 h of treatment (Fig. 5GoD). Treatment with RB6-8C5 2 and 3 days after serum transfer quickly reversed the joint-specific inflammatory reaction, as measured by ankle swelling and clinical scores. Mice that received RB6-8C5 on day 4 (G) and day 5 (H) also showed a rapid decline in ankle thickness beginning ~1 day after treatment, indicating that at this time the inflammation is also reversible or at least can be ameliorated by neutrophil depletion. All of the treated groups showed significant benefit from neutrophil depletion, as determined by reduction in erythema, puffiness, and joint thickness (data not shown). Inhibition of ankle swelling by neutrophil depletion became less effective when initiated after day 3 of serum transfer (Fig. 5GoI). Mice were analyzed for the extent of neutrophil depletion on days 0, 2, 4, and 7 by FACS analysis. By day 5–6 after RB6-8C5 mAb injection, neutrophils began to reappear in peripheral blood due to clearance of Ab from the bloodstream and tissues and maturation and release of neutrophils from the bone marrow. There is a clear correlation between the time of recovery of RB6-8C5+ peripheral neutrophils and the onset or resumption of joint inflammation (data not shown). These studies revealed that the early stages of experimental immune complex-induced arthritis, up to day 3, could be completely reversed by depletion of neutrophils, and disease severity was ameliorated up through day 5. These experiments indicate that not only are neutrophils critically involved during the first 3–5 days of the disease, but they are also required for the continuation and progression of the immune complex-mediated inflammatory state.



View larger version (31K):
[in this window]
[in a new window]
  		FIGURE 5. Reversal of K/BxN serum-induced joint inflammation by neutrophil depletion via RB6-8C5 treatment. Groups of mice were treated with PBS or a single dose of RB6-8C5 (250 µg i.p.) before, concurrent with, or following serum transfer on day 0. Mice were treated with either PBS (A), or RB6-8C5 mAb on day -1 (B), day 0 (C), day +1 (D), day +2 (E), day +3 (F), day +4 (G), or day +5 (H). The time of RB6-8C5 injection is marked with an arrow on the x-axis of each panel. Each panel represents a separate group of four mice, and these results are representative of three identical experiments. All groups receiving RB6-8C5 showed either significant protection from joint disease or dramatic reduction of disease severity following treatment. I, Mean percent inhibition of ankle swelling on day 6 after serum transfer was calculated for each experimental group of mice, as described in Materials and Methods, with PBS control group ankle thickness set to 0% inhibition. Values depicted in I are the mean of three identical experiments totaling 12 mice per experimental group, with SD values indicated by error bars. Statistical significance was determined by paired Student t test analysis (*, p < 0.006; {dagger}, p < 0.013). Ab depletion of neutrophils becomes progressively less effective at reversing disease after sustained joint inflammation.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Transfer of K/BxN serum Ig into recipient mice induces the synchronized and rapid onset of joint inflammation. We used this model to determine the importance of neutrophils in the initiation, progression, and maintenance of inflammatory joint disease in this experimental mouse model of rheumatoid-like polyarthritis. We found that Ab-induced neutrophil depletion caused a complete block in the ability of K/BxN serum to induce joint swelling in recipient mice, and this protection from inflammation could be maintained for periods of at least 7 days with repeated RB6-8C5 Ab treatment. The foot and ankle joint spaces remained free of infiltrating neutrophils by histology, and the synovia of the ankle remained free of cellular infiltrate and were of normal size and morphology. When the neutrophil compartment was allowed to recover by termination of RB6-8C5 treatment, the repopulation of the peripheral blood neutrophil population (by maturation from immature precursor cells) correlated closely with the observed onset of joint inflammation, indicating an active role for neutrophils in the early stages of this disease rather than as late arrivals to well-established sites of inflammation. Joint inflammation could be completely blocked or reversed by neutrophil depletion if initiated by 3 days postserum transfer, but became progressively less effective when initiated at later time points, indicating the probable involvement of other cell types at later stages in the K/BxN serum transfer model. Formation of scar tissue and fibroblast proliferation may also be contributing factors to residual ankle thickening after prolonged inflammation.

This model disease can be transferred to normal mice with purified GPI-specific IgG from arthritic mice (21), strongly suggesting that the initial triggering event is the formation and/or deposition of GPI-IgG immune complexes in the joint spaces. Therefore, it is likely to share features with other immune complex-triggered autoimmune models (11, 41, 42). Local mononuclear cells and possibly mast cells (43) become activated by immune complex-activated complement fragments (44, 45), tissue damage, and/or Fc{gamma}R cross-linking (11, 46), and release proinflammatory cytokines such as IL-1{beta} and TNF-{alpha} (43, 47) in or near the affected tissue (e.g., joints), which induces some relatively low level of neutrophil recruitment. These few initial neutrophils become activated, extravasate, and home to the joints, where they proceed to help create a proinflammatory cytokine milieu that is necessary to maintain and expand the joint inflammatory response. In a rat model of arthritis unrelated to the K/BxN model, repeated injection of streptococcal cell wall extract causes joint inflammation, which has also been shown to be neutrophil dependent and requires P-selectin, ICAM-1, and macrophage-inflammatory protein-2 (48), suggesting these molecules are likely to be important in the K/BxN model for neutrophil recruitment. In the CIA model, it has been clearly demonstrated that autoreactive Abs to type II collagen initiate inflammation by binding to articular cartilage and causing activation of complement, C3 deposition (44), and eventual cleavage of C5 (45). Although the K/BxN RA model is also autoantibody mediated and shares pathology with CIA, the Ag (GPI) is not joint specific (21), and deposition of GPI-autoantibody immune complexes in the joints of mice has yet to be demonstrated, and remains an intriguing question.

Potential neutrophil effector mechanisms that may be critical for the induction and progression of joint inflammation in the murine K/BxN serum transfer model include release of granules containing degradative enzymes, and the production and release of proinflammatory cytokines. Neutrophil granule contents such as myeloperoxidase, elastase, matrix metalloproteinases, and collagenase (41, 49) can cause further damage to the tissue and amplify the neutrophil response, which has been observed in an Ab-mediated model of bullous pemphigoid (50). Alternatively, activated neutrophils are also capable of releasing proinflammatory cytokines such as TNF-{alpha}, IL-1, IL-6, and TGF{beta} (51, 52), potentially affecting the activities of both neutrophils and other cell types, such as resident mononuclear cells and chondrocytes. TNF-{alpha} is at the apex of a proposed cascade model of proinflammatory cytokines in rheumatoid synovial tissue (2), and the role of TNF-{alpha} as a dominant proarthritogenic cytokine has been demonstrated with mice transgenic for human TNF-{alpha} (53). Neutrophils may also interfere with the balance of IL-1 and endogenous IL-1 receptor antagonist (IL-1ra) activity in the joint (54), either by direct secretion of IL-1 or through TNF-{alpha}-mediated IL-1 induction. Mice that are deficient in the endogenous IL-1ra develop a chronic, progressive joint inflammation disease on certain mouse backgrounds, illustrating the importance of a balance between IL-1 and IL-1ra in normal joint physiology and homeostasis of inflammatory cytokines.

Finally, TGF{beta} is another proinflammatory cytokine found in synovial tissue and fluid (55) and is a powerful neutrophil chemoattractant (56). As with TNF-{alpha} and IL-1, neutrophils can both produce and respond to TGF{beta}, providing a potential amplification mechanism for continued neutrophil activation and recruitment. In combination with their capacity to make TNF-{alpha} and IL-1, one can propose a model for K/BxN serum transfer in which initial mononuclear cell activation and cytokine release in the joint tissues induces some level of initial neutrophil recruitment. The initial wave of recruited neutrophils would then be largely responsible for amplifying and sustaining recruitment of neutrophils to the inflamed tissues through the continued generation and release of proinflammatory cytokines such as TNF-{alpha}, IL-1, and TGF{beta}.

In contrast to cytokine secretion and degranulation of proenzymes that are usually directed toward extracellular targets, the oxidative species produced by the iNOS pathway (e.g., NO) and the NADPH oxidase pathway (hydrogen peroxide) are usually directed intracellularly against phagocytosed bacteria or particles contained within a phagosome. However, it has recently been proposed (49) that adherent neutrophils could release such reactive species into small pockets of synovial fluid, leading to inappropriate activation of proenzymes such as elastase or metallothionein proteases, and damage of the synovial fluid hyaluronan or cartilage. In several model systems of immunopathologic disease, inhibition of either NADPH or iNOS pathways or both together has yielded a reduction in the severity of inflammation or disease (29, 57, 58). Unexpectedly, we found that mice deficient for either gp91phox or iNOS2 activity presented similar disease phenotypes as wild-type control mice. There was no significant reduction in the severity of disease induced by K/BxN serum transfer, nor was there any significant alteration in the time of disease onset for these mutant strains of mice. Interestingly, iNOS2 knockout mice demonstrated enhanced swelling relative to B6 mice in two of three experiments. This suggests that neither of these two pathways are obligatory for immune complex-triggered joint inflammation in the K/BxN serum transfer model, although one might expect that they are likely to be involved in tissue damage once a joint becomes inflamed. Indeed, other studies have shown that overproduction of NO and its reaction product, peroxynitrate, contributes to the pathophysiology of RA and joint inflammation (59, 60).

To summarize, it has been hypothesized, but not directly shown, that neutrophils are an important component of inflammatory responses to immune complex deposition in the joints because they are found there in high numbers. This study convincingly demonstrates that neutrophils are an essential component of the K/BxN autoreactive IgG transfer model of rheumatoid-like arthritis, and that an induced state of neutropenia confers protection from joint-specific inflammation. These results are important because they demonstrate for the first time that neutrophils play an essential inductive role in the generation of joint-specific inflammation in the K/BxN serum transfer model (e.g., one or more of the properties of neutrophils are responsible for early stages of inflammation in the K/BxN). The mechanism by which neutrophils are recruited specifically to the joint in the K/BxN model, and which neutrophil characteristics are important in this location, are questions that bear further consideration and will be the subject of future experiments. Further studies to elucidate the exact operative mechanisms exerted by neutrophils may point to potential approaches for pharmacological intervention in other inflammatory diseases such as human RA, to help ameliorate or limit the severity and scope of joint disease.


   Acknowledgments
 
We thank Diane Mathis and Christophe Benoist for providing us with the K/BxN mouse strain, and Emil Unanue, Eric Brown, Laura Mandik-Nayak, and Aleksandra Colic for critical reviews of this manuscript. We also thank Emil Unanue for the RB6-8C5 Ab and hybridoma. Darren Kreamalmeyer’s expert management of our mouse colony was invaluable. We also thank the Histology Core Facilities of the Departments of Pathology and Molecular Microbiology & Pharmacology for their aid in preparing histological sections for this body of work, and greatly appreciate the secretarial efforts of Jerri Smith in the preparation of this manuscript.


   Footnotes
 
1 This work was supported by National Institutes of Health Research Grant AI 31238. Back

2 Address correspondence and reprint requests to Dr. Paul M. Allen, Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8118, St. Louis, MO 63110. E-mail address: allen{at}immunology.wustl.edu Back

3 Abbreviations used in this paper: RA, rheumatoid arthritis; CIA, collagen-induced arthritis; GPI, glucose-6-phosphate isomerase; IL-1ra, IL-1 receptor antagonist; iNOS, inducible NO synthase; NOD, nonobese diabetic. Back

Received for publication January 10, 2001. Accepted for publication May 18, 2001.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Feldmann, M., F. M. Brennan, R. N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14:397.[Medline]
  2. Brennan, F. M., R. N. Maini, M. Feldmann. 1998. Role of proinflammatory cytokines in rheumatoid arthritis. Springer Semin. Immunopathol. 20:133.[Medline]
  3. Loutis, N., P. Bruckner, A. Pataki. 1988. Induction of erosive arthritis in mice after passive transfer of anti-type II collagen antibodies. Agents Actions 25:352.[Medline]
  4. Stuart, J. M., M. A. Cremer, A. S. Townes, A. H. Kang. 1982. Type II collagen-induced arthritis in rats: passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J. Exp. Med. 155:1.[Abstract/Free Full Text]
  5. Trentham, D. E., A. S. Townes, A. H. Kang. 1977. Autoimmunity to type II collagen: an experimental model of arthritis. J. Exp. Med. 146:857.[Abstract/Free Full Text]
  6. Watson, W. C., P. S. Brown, J. A. Pitcock, A. S. Townes. 1987. Passive transfer studies with type II collagen antibody in B10.D2/old and new line and C57BL/6 normal and beige (Chediak-Higashi) strains: evidence of important roles for C5 and multiple inflammatory cell types in the development of erosive arthritis. Arthritis Rheum. 30:460.[Medline]
  7. Wooley, P. H., H. S. Luthra, J. M. Stuart, C. S. David. 1981. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J. Exp. Med. 154:688.[Abstract/Free Full Text]
  8. Myers, L. K., E. F. Rosloniec, M. A. Cremer, A. H. Kang. 1997. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci. 61:1861.[Medline]
  9. Holmdahl, R., K. Rubin, L. Klareskog, E. Larsson, H. Wigzell. 1986. Characterization of the antibody response in mice with type II collagen-induced arthritis, using monoclonal anti-type II collagen antibodies. Arthritis Rheum. 29:400.[Medline]
  10. Terato, K., K. A. Hasty, R. A. Reife, M. A. Cremer, A. H. Kang, J. M. Stuart. 1992. Induction of arthritis with monoclonal antibodies to collagen. J. Immunol. 148:2103.[Abstract]
  11. Kleinau, S., P. Martinsson, B. Heyman. 2000. Induction and suppression of collagen-induced arthritis is dependent on distinct Fc{gamma} receptors. J. Exp. Med. 191:1611.[Abstract/Free Full Text]
  12. Geiger, T., H. Towbin, A. Cosenti-Vargas, O. Zingel, J. Arnold, C. Rordorf, M. Glatt, K. Vosbeck. 1993. Neutralization of interleukin-1{beta} activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response. Clin. Exp. Rheumatol. 11:515.[Medline]
  13. Butler, D. M., A.-M. Malfait, R. N. Maini, F. M. Brennan, M. Feldmann. 1999. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur. J. Immunol. 29:2205.[Medline]
  14. Piguet, P. F., G. E. Grau, C. Vesin, H. Loetscher, R. Gentz, W. Lesslauer. 1992. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumor necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77:510.[Medline]
  15. Thorbecke, G. J., R. Shah, C. H. Leu, A. P. Kuruvilla, A. M. Hardison, M. A. Palladino. 1992. Involvement of endogenous tumor necrosis factor {alpha} and transforming growth factor {beta} during induction of collagen type II arthritis in mice. Proc. Natl. Acad. Sci. USA 89:7375.[Abstract/Free Full Text]
  16. Williams, R. O., M. Feldmann, R. N. Maini. 1992. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89:9784.[Abstract/Free Full Text]
  17. Kouskoff, V., A.-S. Korganow, V. Duchatelle, C. Degott, C. Benoist, D. Mathis. 1996. Organ-specific disease provoked by systemic autoimmunity. Cell 87:811.[Medline]
  18. Korganow, A.-S., H. Ji, S. Mangialaio, V. Duchatelle, R. Pelanda, T. Martin, C. Degott, H. Kikutani, K. Rajewsky, J.-L. Pasquali, C. Benoist, D. Mathis. 1999. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10:451.[Medline]
  19. Chen, P. P., S. Fong, D. A. Carson. 1987. Rheumatoid factor. Rheum. Dis. Clin. N. Am. 13:545.[Medline]
  20. Winchester, R. J., V. Agnello, H. G. Kunkel. 1970. Gammaglobulin complexes in synovial fluids of patients with rheumatoid arthritis: partial characterization and relationship to lowered complement levels. Clin. Exp. Immunol. 6:689.[Medline]
  21. Matsumoto, I., A. Staub, C. Benoist, D. Mathis. 1999. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286:1732.[Abstract/Free Full Text]
  22. Basu, D., S. Horvath, I. Matsumoto, D. H. Fremont, P. M. Allen. 2000. Molecular basis for recognition of an arthritic peptide and a foreign epitope on distinct MHC molecules by a single TCR. J. Immunol. 164:5788.[Abstract/Free Full Text]
  23. Basu, D., S. Horvath, L. O’Mara, D. Donermeyer, P. M. Allen. 2001. Two MHC surface amino acid differences distinguish foreign peptide recognition from autoantigen specificity. J. Immunol. 166:4005.[Abstract/Free Full Text]
  24. Laubach, V. E., E. G. Shesely, O. Smithies, P. A. Sherman. 1995. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc. Natl. Acad. Sci. USA 92:10688.[Abstract/Free Full Text]
  25. Pollock, J. D., D. A. Williams, M. A. Gifford, L. L. Li, X. Du, J. Fisherman, S. H. Orkin, C. M. Doerschuk, M. C. Dinauer. 1995. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat. Genet. 9:202.[Medline]
  26. Hestdal, K., F. W. Ruscetti, J. N. Ihle, S. E. Jacobsen, C. M. Dubois, W. C. Kopp, D. L. Longo, J. R. Keller. 1991. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J. Immunol. 147:22.[Abstract]
  27. Dialynas, D. P., Z. S. Quan, K. A. Wall, A. Pierres, J. Quintans, M. R. Loken, M. Pierres, F. W. Fitch. 1983. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J. Immunol. 131:2445.[Abstract]
  28. Rogers, H. W., E. R. Unanue. 1993. Neutrophils are involved in acute, nonspecific resistance to Listeria monocytogenes in mice. Infect. Immun. 61:5090.[Abstract/Free Full Text]
  29. Andrews, D. M., V. B. Matthews, L. M. Sammels, A. C. Carrello, P. C. McMinn. 1999. The severity of murray valley encephalitis in mice is linked to neutrophil infiltration and inducible nitric oxide synthase activity in the central nervous system. J. Virol. 73:8781.[Abstract/Free Full Text]
  30. Verdrengh, M., A. Tarkowski. 1997. Role of neutrophils in experimental septicemia and septic arthritis induced by Staphylococcus aureus. Infect. Immun. 65:2517.[Abstract]
  31. Conlan, J. W.. 1997. Critical roles of neutrophils in host defense against experimental systemic infections of mice by Listeria monocytogenes, Salmonella typhimurium, and Yersinia enterocolitica. Infect. Immun. 65:630.[Abstract]
  32. Conlan, J. W., R. J. North. 1994. Neutrophils are essential for early anti-Listeria defense in the liver, but not in the spleen or peritoneal cavity, as revealed by a granulocyte-depleting monoclonal antibody. J. Exp. Med. 179:259.[Abstract/Free Full Text]
  33. Pedrosa, J., B. M. Saunders, R. Appelberg, I. M. Orme, M. T. Silva, A. M. Cooper. 2000. Neutrophils play a protective nonphagocytic role in systemic Mycobacterium tuberculosis infection of mice. Infect. Immun. 68:577.[Abstract/Free Full Text]
  34. Saunders, B. M., C. Cheers. 1996. Intranasal infection of beige mice with Mycobacterium avium complex: role of neutrophils and natural killer cells. Infect. Immun. 64:4236.[Abstract]
  35. Tateda, K., T. A. Moore, J. C. Deng, M. W. Newstead, X. Zeng, A. Matsukawa, M. S. Swanson, K. Yamaguchi, T. J. Standiford. 2001. Early recruitment of neutrophils determines subsequent T1/T2 host responses in a murine model of Legionella pneumophila pneumonia. J. Immunol. 166:3355.[Abstract/Free Full Text]
  36. Tumpey, T. M., S.-H. Chen, J. E. Oakes, R. N. Lausch. 1996. Neutrophil-mediated suppression of virus replication after herpes simplex virus type 1 infection of the murine cornea. J. Virol. 70:898.[Abstract]
  37. Kielian, T., B. Barry, W. F. Hickey. 2001. CXC chemokine receptor-2 ligands are required for neutrophil-mediated host defense in experimental brain abscesses. J. Immunol. 166:4634.[Abstract/Free Full Text]
  38. De Oca, R. M., A. J. Buendia, L. Del Rio, J. Sanchez, J. Salinas, J. A. Navarro. 2000. Polymorphonuclear neutrophils are necessary for the recruitment of CD8+ T cells in the liver in a pregnant mouse model of Chlamydophila abortus (Chlamydia psittaci serotype 1) infection. Infect. Immun. 68:1746.[Abstract/Free Full Text]
  39. Goossens, P. L., H. Jouin, G. Milon. 1991. Dynamics of lymphocytes and inflammatory cells recruited in liver during murine listeriosis: a cytofluorimetric study. J. Immunol. 147:3514.[Abstract]
  40. Barteneva, N., I. Theodor, E. M. Peterson, L. M. de la Maza. 1996. Role of neutrophils in controlling early stages of a Chlamydia trachomatis infection. Infect. Immun. 64:4830.[Abstract]
  41. Witko-Sarsat, V., P. Rieu, B. Descamps-Latscha, P. Lesavre, L. Halbwachs-Mecarelli. 2000. Neutrophils: molecules, functions and pathophysiological aspects. Lab. Invest. 80:617.[Medline]
  42. Heller, T., J. E. Gessner, R. E. Schmidt, A. Klos, W. Bautsch, J. Kohl. 1999. Cutting edge: Fc receptor type I for IgG on macrophages and complement mediates the inflammatory response in immune complex peritonitis. J. Immunol. 162:5657.[Abstract/Free Full Text]
  43. Zhang, Y., B. F. Ramos, B. A. Jakschik. 1992. Neutrophil recruitment by tumor necrosis factor from mast cells in immune complex peritonitis. Science 258:1957.[Abstract/Free Full Text]
  44. Stuart, J. M., F. J. Dixon. 1983. Serum transfer of collagen-induced arthritis in mice. J. Exp. Med. 158:378.[Abstract/Free Full Text]
  45. Wang, Y., S. A. Rollins, J. A. Madri, L. A. Matis. 1995. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. USA 92:8955.[Abstract/Free Full Text]
  46. Blom, A. B., P. L. van Lent, H. van Vuuren, A. E. Holthuysen, C. Jacobs, L. B. van De Putte, J. G. van De Winkel, W. B. van Den Berg. 2000. Fc{gamma}R expression on macrophages is related to severity and chronicity of synovial inflammation and cartilage destruction during experimental immune-complex-mediated arthritis (ICA). Arthritis Res. 2:489.[Medline]
  47. Warren, J. S.. 1992. Relationship between interleukin-1{beta} and platelet-activating factor in the pathogenesis of acute immune complex alveolitis in the rat. Am. J. Pathol. 141:551.[Abstract]
  48. Schimmer, R. C., D. J. Schrier, C. M. Flory, J. Dykens, D. K. Tung, P. B. Jacobson, H. P. Friedl, M. C. Conroy, B. B. Schimmer, P. A. Ward. 1997. Streptococcal cell wall-induced arthritis: requirements for neutrophils, P-selectin, intercellular adhesion molecule-1, and macrophage-inflammatory protein-2. J. Immunol. 159:4103.[Abstract]
  49. Pillinger, M. H., S. B. Abramson. 1995. The neutrophil in rheumatoid arthritis. Rheum. Dis. Clin. N. Am. 21:691.[Medline]
  50. Liu, Z., S. D. Shapiro, X. Zhou, S. S. Twining, R. M. Senior, G. J. Giudice, J. A. Fairley, L. A. Diaz. 2000. A critical role for neutrophil elastase in experimental bullous pemphigoid. J. Clin. Invest. 105:113.[Medline]
  51. Fava, R. A., N. J. Olsen, A. E. Postlethwaite, K. N. Broadley, J. M. Davidson, L. B. Nanney, C. Lucas, A. S. Townes. 1991. Transforming growth factor {beta}1 (TGF-{beta}1) induced neutrophil recruitment to synovial tissues: implications for TGF-{beta}-driven synovial inflammation and hyperplasia. J. Exp. Med. 173:1121.[Abstract/Free Full Text]
  52. Cassatella, M. A., S. Gasperini, M. P. Russo. 1997. Cytokine expression and release by neutrophils. Ann. NY Acad. Sci. 832:233.[Free Full Text]
  53. Butler, D. M., A.-M. Malfait, L. J. Mason, P. J. Warden, G. Kollias, R. N. Maini, M. Feldmann, F. M. Brennan. 1997. DBA/1 mice expressing the human TNF-{alpha} transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J. Immunol. 159:2867.[Abstract]
  54. Horai, R., S. Saijo, H. Tanioka, S. Nakae, K. Sudo, A. Okahara, T. Ikuse, M. Asano, Y. Iwakura. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191:313.[Abstract/Free Full Text]
  55. Wahl, S. M., J. B. Allen, H. L. Wong, S. F. Dougherty, L. R. Ellingsworth. 1990. Antagonistic and agonistic effects of transforming growth factor-{beta} and IL-1 in rheumatoid synovium. J. Immunol. 145:2514.[Abstract]
  56. Brandes, M. E., U. E. Mai, K. Ohura, S. M. Wahl. 1991. Type I transforming growth factor-{beta} receptors on neutrophils mediate chemotaxis to transforming growth factor-{beta}. J. Immunol. 147:1600.[Abstract]
  57. Kakimoto, K., Y. Kojima, K. Ishii, K. Onoue, H. Maeda. 1993. The suppressive effect of gelatin-conjugated superoxide dismutase on disease development and severity of collagen-induced arthritis in mice. Clin. Exp. Immunol. 94:241.[Medline]
  58. Kubo, H., D. Morgenstern, W. M. Quinian, P. A. Ward, M. C. Dinauer, C. M. Doerschuk. 1996. Preservation of complement-induced lung injury in mice with deficiency of NADPH oxidase. J. Clin. Invest. 97:2680.[Medline]
  59. Connor, J. R., P. T. Manning, S. L. Settle, W. M. Moore, G. M. Jerome, R. K. Webber, F. S. Tjoeng, M. G. Currie. 1995. Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur. J. Pharmacol. 273:15.[Medline]
  60. McCartney-Francis, N., J. B. Allen, D. E. Mizel, J. E. Albina, Q. W. Xie, C. F. Nathan, S. M. Wahl. 1993. Suppression of arthritis by an inhibitor of nitric oxide synthase. J. Exp. Med. 178:749.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J EndocrinolHome page
E. Himpe, C. Degaillier, A. Coppens, and R. Kooijman
Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway
J. Endocrinol., October 1, 2008; 199(1): 69 - 80.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
V. Elgazar-Carmon, A. Rudich, N. Hadad, and R. Levy
Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding
J. Lipid Res., September 1, 2008; 49(9): 1894 - 1903.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. Boross, P. L. van Lent, J. Martin-Ramirez, J. van der Kaa, M. H. C. M. Mulder, J. W. C. Claassens, W. B. van den Berg, V. L. Arandhara, and J. S. Verbeek
Destructive Arthritis in the Absence of Both Fc{gamma}RI and Fc{gamma}RIII
J. Immunol., April 1, 2008; 180(7): 5083 - 5091.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
R. L. Schmidt, T. R. Trejo, T. B. Plummer, J. L. Platt, and A. H. Tang
Infection-induced proteolysis of PGRP-LC controls the IMD activation and melanization cascades in Drosophila
FASEB J, March 1, 2008; 22(3): 918 - 929.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
K. Abe, S. Wechs, S. Kalaydjiev, T. J. Franz, D. H. Busch, H. Fuchs, D. Soewarto, H. Behrendt, S. Wagner, T. Jakob, et al.
Novel lymphocyte-independent mechanisms to initiate inflammatory arthritis via bone marrow-derived cells of Ali18 mutant mice
Rheumatology, March 1, 2008; 47(3): 292 - 300.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Z. Jakus, T. Nemeth, J. S. Verbeek, and A. Mocsai
Critical but Overlapping Role of Fc{gamma}RIII and Fc{gamma}RIV in Activation of Murine Neutrophils by Immobilized Immune Complexes
J. Immunol., January 1, 2008; 180(1): 618 - 629.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
J. S. Zhou, W. Xing, D. S. Friend, K. F. Austen, and H. R. Katz
Mast cell deficiency in KitW-sh mice does not impair antibody-mediated arthritis